Stansberry Asset Management LLC raised its position in Celgene Co. (NASDAQ:CELG) by 62.0% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 388,416 shares of the biopharmaceutical company’s stock after buying an additional 148,726 shares during the period. Celgene comprises 14.1% of Stansberry Asset Management LLC’s investment portfolio, making the stock its biggest position. Stansberry Asset Management LLC owned approximately 0.05% of Celgene worth $35,905,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in CELG. Oregon Public Employees Retirement Fund increased its stake in shares of Celgene by 4.6% during the second quarter. Oregon Public Employees Retirement Fund now owns 273,716 shares of the biopharmaceutical company’s stock worth $25,302,000 after purchasing an additional 12,071 shares in the last quarter. Gilman Hill Asset Management LLC increased its stake in shares of Celgene by 18.6% during the second quarter. Gilman Hill Asset Management LLC now owns 7,416 shares of the biopharmaceutical company’s stock worth $686,000 after purchasing an additional 1,165 shares in the last quarter. Canyon Capital Advisors LLC purchased a new stake in shares of Celgene during the first quarter worth about $119,226,000. Ruffer LLP purchased a new stake in shares of Celgene during the first quarter worth about $226,613,000. Finally, Gyroscope Capital Management Group LLC increased its stake in shares of Celgene by 583.1% during the second quarter. Gyroscope Capital Management Group LLC now owns 104,263 shares of the biopharmaceutical company’s stock worth $9,769,000 after purchasing an additional 89,000 shares in the last quarter. 72.41% of the stock is owned by institutional investors.
A number of analysts have recently commented on the stock. Mizuho cut shares of Celgene from a “buy” rating to a “neutral” rating and cut their target price for the stock from $103.00 to $100.00 in a research note on Monday, August 19th. ValuEngine cut shares of Celgene from a “sell” rating to a “strong sell” rating in a research note on Thursday, August 1st. Zacks Investment Research raised shares of Celgene from a “sell” rating to a “hold” rating and set a $94.00 target price for the company in a research note on Tuesday, July 23rd. BidaskClub cut shares of Celgene from a “buy” rating to a “hold” rating in a research note on Saturday, September 7th. Finally, Cowen reissued a “hold” rating and set a $102.00 target price on shares of Celgene in a research note on Tuesday, July 30th. One investment analyst has rated the stock with a sell rating, eighteen have given a hold rating and three have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $94.60.
Celgene (NASDAQ:CELG) last announced its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $2.61 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.44 by $0.17. Celgene had a net margin of 32.24% and a return on equity of 89.93%. The company had revenue of $4.40 billion during the quarter, compared to analysts’ expectations of $4.22 billion. During the same quarter in the prior year, the company earned $2.16 EPS. Celgene’s revenue was up 15.4% compared to the same quarter last year. On average, equities research analysts predict that Celgene Co. will post 9.96 EPS for the current year.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Read More: How to Use the New Google Finance Tool
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.